JX-594 + cyclophosphamide

JX-594 + cyclophosphamide is a combination therapy consisting of JX-594 (also known as Pexa-Vec or pexastimogene devacirepvec), an oncolytic vaccinia virus engineered to selectively replicate in and destroy cancer cells, and cyclophosphamide, a well-established alkylating chemotherapeutic agent. JX-594 is designed to target tumor cells through multiple mechanisms: - Direct lysis of infected cancer cells via selective viral replication. - Induction of anti-tumor immunity by expressing granulocyte-macrophage colony-stimulating factor (GM-CSF), which activates dendritic cells and enhances immune response. - Disruption of tumor vasculature leading to vascular shutdown within tumors. The virus is engineered with the GM-CSF gene insertion and deletion of the thymidine kinase gene for tumor selectivity. Cyclophosphamide acts as an immunomodulatory chemotherapeutic that can further enhance anti-tumor effects by reducing regulatory T cell populations or modulating the immune microenvironment. This combination aims to maximize direct oncolytic activity while boosting systemic anti-tumor immunity[1][2][3].

Brand names

Pexa-Vec

Other names

JX-594 + cyclophosphamide